The latest announcement is out from Microbot Medical Inc (MBOT).
Microbot Medical Inc. has made available its latest presentation materials on its website, signaling key regulatory milestones with anticipated 510(k) clearance from the US FDA and CE Mark approval expected in 2025. However, the company clarifies these projections as forward-looking statements and acknowledges that actual results may vary. Investors are reminded to consider the associated risk factors and not to take the information as an admission of materiality or a guarantee of future outcomes.
See more insights into MBOT stock on TipRanks’ Stock Analysis page.
